MENS
What one share of Jyong Biotech holds
Pharmaceutical Preparations
We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public.
Jyong Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.06 |
|---|---|
| Cash and investments | $0.02 |
| Debt | $0.23 |
| Book value | −$0.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$0.06 | — | −$0.04 | — | −$0.48 |
| 2024 | — | −$0.04 | — | −$0.05 | — | −$0.50 |
| 2025 | — | −$0.06 | — | −$0.04 | — | −$0.33 |